ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

No Evidence Of Fraud Found In NCI Audit Of NSABP Trials

April 29, 1994

PHS Plans Revitalization of Commissioned Corps

July 11, 2003

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002

NCI-Approved Clinical Trials

September 29, 2006

FDA Approves Arranon For Leukemia And Lymphoma

December 30, 2005

Senate Raises Funding For Cervical, Ovarian, Prostate Cancer

September 18, 1992